GLP-1薬は年齢・人種を超えて有効（GLP-1 drugs comparably effective across age, race, and starting weight）

2026-03-04

2026-03-03 ジョンズ・ホプキンス大学（JHU）

ジョンズ・ホプキンス大学の研究チームは、GLP-1受容体作動薬がさまざまな人口集団において一貫して有効であることを示した。GLP-1系薬剤は糖尿病や肥満治療に広く用いられているが、その効果が人種、年齢、性別などの違いによって変化するかは十分に検証されていなかった。研究では臨床データを分析し、GLP-1薬が多様な患者群で体重減少や血糖コントロールの改善に有効であることを確認した。結果は、これらの薬剤が特定の人口層に限定されず広く効果を示す可能性を示しており、肥満や2型糖尿病の治療戦略における重要な選択肢であることを裏付けている。また、今後の医療政策や治療ガイドラインの検討にも有用な知見を提供するとしている。

＜関連情報＞

成人における減量に対するグルカゴン様ペプチド-1受容体作動薬の治療効果の異質性体系的レビューとメタ分析 Heterogeneity of Treatment Effects of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss in Adults A Systematic Review and Meta-Analysis

G. Caleb Alexander, MD, MS; Xuya Xiao, MHS; Sophie Dilek, MPH;et al
JAMA Internal Medicine Published:March 2, 2026
DOI:10.1001/jamainternmed.2025.8222

Key Points

Question How heterogeneous are the treatment effects of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) on weight loss, by age, sex, race and ethnicity, baseline body mass index, and baseline hemoglobin A_1c?

Findings In this systematic review and meta-analysis of 41 articles representing 64 randomized clinical trials, the efficacy of GLP-1 RAs was greater among women than men but did not otherwise differ by age, race and ethnicity, baseline body mass index, or baseline hemoglobin A_1c.

Meaning Except for the difference by sex, the efficacy of GLP-1 RAs for weight loss appears to be consistent across many important subpopulations of patients who may be eligible for treatment.

Abstract

Importance Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a novel class of therapeutics approved to treat chronic conditions such as cardiovascular disease, diabetes, and/or obesity. However, whether GLP-1 RAs’ efficacy varies by age, sex, race and ethnicity, baseline body mass index (BMI), and baseline hemoglobin A_1c (HbA_1c) is unclear.

Objective To quantify the heterogeneity of treatment effects (HTE) of GLP-1 RAs, including semaglutide, liraglutide, exenatide, lixisenatide, and dulaglutide, by patient characteristics.

Data Sources MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials, from inception through July 26, 2024.

Study Selection Pairs of investigators independently screened titles and abstracts and then reviewed eligible full-text articles reporting on randomized clinical trials (RCTs) that compared GLP-1 RAs to placebo or other medications.

Data Extraction and Synthesis Study design, interventions, and comparators, and patient baseline weight and weight change over time (overall and by age, sex, race and ethnicity, BMI, and HbA_1c level) were extracted from the data. Risk of bias was assessed using the Cochrane risk of bias tool and meta-analyses were conducted using random-effects models. For each subgroup, RCTs were meta-analyzed where quantitative synthesis was possible, while additional relevant studies were narratively incorporated in the analysis.

Main Outcomes and Measures Change in body weight measured in kg (by age, baseline BMI, baseline HbA_1c) or percentage change from baseline (by sex, race and ethnicity).

Results Of 7705 unique records, 41 articles representing 64 RCTs were included in the meta-analysis. Of these, 48 RCTs could be individually characterized: they had a mean (SD) study population of 1181 (2513) participants; 51 trials were parallel (98.1%); 51 multicenter (98.1%); and 21 evaluated semaglutide (43.8%) and 9, dulaglutide (18.8%). HTE was most commonly evaluated using baseline BMI (36 RCTs [75.0%]), HbA_1c (24 [50.0%]), and age (21 [43.8%]), and less commonly, ethnicity (12 [25.0%]), race (11 [22.9%]), and sex (10 [20.8%]). Among 6 trials (19 906 patients) analyzed by sex, weight loss was greater among women (10.9%; 95% CI, 7.0%-14.8%) than men (6.8%; 95% CI, 4.6%-9.0%). We found no significant HTE by age (7 trials with 4314 patients), race (9 trials, 25 229 patients), ethnicity (7 trials, 8328 patients), baseline BMI (15 trials, 9473 patients across 3 analyses), or baseline HbA_1c (4 trials, 1886 patients).

Conclusions and Relevance In this systematic review and meta-analysis, GLP-1 RAs produced greater weight loss among women than men; however, their efficacy was consistent across other important subpopulations. These findings may inform clinical decision-making.